标题
Role of bromodomain and extraterminal (BET) proteins in prostate cancer
作者
关键词
-
出版物
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 32, Issue 3, Pages 213-228
出版商
Informa UK Limited
发表日期
2023-03-02
DOI
10.1080/13543784.2023.2186851
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- PROTAC targeted protein degraders: the past is prologue
- (2022) Miklós Békés et al. NATURE REVIEWS DRUG DISCOVERY
- Evaluation of JQ1 Combined With Docetaxel for the Treatment of Prostate Cancer Cells in 2D- and 3D-Culture Systems
- (2022) Yipeng Xu et al. Frontiers in Pharmacology
- BET bromodomain inhibitors
- (2022) Martin P. Schwalm et al. CURRENT OPINION IN CHEMICAL BIOLOGY
- Novel forms of prostate cancer chemoresistance to successful androgen deprivation therapy demand new approaches: Rationale for targeting BET proteins
- (2022) Joakin O. Mori et al. PROSTATE
- Phase Ib Study of the BET Inhibitor GS-5829 as Monotherapy and Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer
- (2022) Rahul Aggarwal et al. CLINICAL CANCER RESEARCH
- New approaches to targeting epigenetic regulation in prostate cancer
- (2022) Daryl Thompson et al. CURRENT OPINION IN UROLOGY
- BRD4 and MYC : power couple in transcription and disease
- (2022) Aparna Kotekar et al. FEBS Journal
- The Role of Epigenetic Change in Therapy-Induced Neuroendocrine Prostate Cancer Lineage Plasticity
- (2022) William K. Storck et al. Frontiers in Endocrinology
- Retinoblastoma protein as an intrinsic BRD4 inhibitor modulates small molecule BET inhibitor sensitivity in cancer
- (2022) Donglin Ding et al. Nature Communications
- Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell Carcinoma
- (2021) Shogo Shigeta et al. MOLECULAR CANCER THERAPEUTICS
- Prostate-Specific Membrane Antigen Uptake and Survival in Metastatic Castration-Resistant Prostate Cancer
- (2021) Panagiotis J. Vlachostergios et al. Frontiers in Oncology
- Achieving clinical success with BET inhibitors as anti-cancer agents
- (2021) Tatiana Shorstova et al. BRITISH JOURNAL OF CANCER
- Recent Advances in Epigenetic Biomarkers and Epigenetic Targeting in Prostate Cancer
- (2021) Anbarasu Kumaraswamy et al. EUROPEAN UROLOGY
- The role of the deubiquitinating enzyme DUB3/USP17 in cancer: a narrative review
- (2021) Guang-Fei Yang et al. Cancer Cell International
- BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program
- (2021) Dae-Hwan Kim et al. CLINICAL CANCER RESEARCH
- Targeting the spectrum of immune checkpoints in prostate cancer
- (2021) Laura A. Sena et al. Expert Review of Clinical Pharmacology
- Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein of the testis carcinoma and other cancers: Results of a Phase I / II open‐label, dose escalation study
- (2021) Sophie Cousin et al. INTERNATIONAL JOURNAL OF CANCER
- BET Proteins as Attractive Targets for Cancer Therapeutics
- (2021) Joanna Sarnik et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- The combined effect of epigenetic inhibitors for LSD1 and BRD4 alters prostate cancer growth and invasion
- (2020) Jianlin Wang et al. Aging-US
- Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer
- (2020) Emily J. Faivre et al. NATURE
- Make your best BET: The emerging role of BET inhibitor treatment in malignant tumors
- (2020) Oliver Bechter et al. PHARMACOLOGY & THERAPEUTICS
- MYC protein stability is negatively regulated by BRD4
- (2020) Ballachanda N. Devaiah et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Selective targeting of BD1 and BD2 of the BET proteins in cancer and immuno-inflammation
- (2020) Omer Gilan et al. SCIENCE
- BET inhibition therapy counteracts cancer cell survival, clonogenic potential and radioresistance mechanisms in rhabdomyosarcoma cells
- (2020) Simona Camero et al. CANCER LETTERS
- A Phase 1b/2a Study of the Pan-BET Bromodomain Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer
- (2020) Rahul R. Aggarwal et al. CLINICAL CANCER RESEARCH
- BRD4 regulates key transcription factors that drive epithelial–mesenchymal transition in castration-resistant prostate cancer
- (2020) Jordan S. Shafran et al. PROSTATE CANCER AND PROSTATIC DISEASES
- First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours
- (2020) Malaka Ameratunga et al. BRITISH JOURNAL OF CANCER
- Managing toxicities of phosphatidylinositol-3-kinase (PI3K) inhibitors
- (2020) Ashley Hanlon et al. Hematology-American Society of Hematology Education Program
- BET bromodomain inhibition blocks the function of a critical AR-independent master regulator network in lethal prostate cancer
- (2019) Daniel J. Coleman et al. ONCOGENE
- Genomic correlates of clinical outcome in advanced prostate cancer
- (2019) Wassim Abida et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Wnt-pathway Activating Mutations Are Associated with Resistance to First-line Abiraterone and Enzalutamide in Castration-resistant Prostate Cancer
- (2019) Pedro Isaacsson Velho et al. EUROPEAN UROLOGY
- First-in-Human Study of Mivebresib (ABBV-075), an Oral Pan-Inhibitor of Bromodomain and Extra Terminal Proteins, in Patients with Relapsed/Refractory Solid Tumors
- (2019) Sarina A. Piha-Paul et al. CLINICAL CANCER RESEARCH
- Molecular basis for class side effects associated with PI3K/AKT/mTOR pathway inhibitors
- (2019) Ying Zhang et al. Expert Opinion on Drug Metabolism & Toxicology
- Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study
- (2019) Emmanuel S. Antonarakis et al. JOURNAL OF CLINICAL ONCOLOGY
- Immunogenicity of prostate cancer is augmented by BET bromodomain inhibition
- (2019) Wendy Mao et al. Journal for ImmunoTherapy of Cancer
- Dual inhibition of BRD4 and PI3K by SF2523 suppresses human prostate cancer cell growth in vitro and in vivo
- (2018) Gang Shen et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC)
- (2018) Jonathan Welti et al. CLINICAL CANCER RESEARCH
- Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors
- (2018) Jeremy Lewin et al. JOURNAL OF CLINICAL ONCOLOGY
- Bromodomain-containing proteins in prostate cancer
- (2018) Alfonso Urbanucci et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- LSD1 activates a lethal prostate cancer gene network independently of its demethylase function
- (2018) Archana Sehrawat et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- BRD4 Promotes DNA Repair and Mediates the Formation of TMPRSS2-ERG Gene Rearrangements in Prostate Cancer
- (2018) Xiangyi Li et al. Cell Reports
- Targeting the BRD4-HOXB13 Co-regulated Transcriptional Networks with Bromodomain-Kinase Inhibitors to Suppress Metastatic Castration-Resistant Prostate Cancer
- (2018) Niveditha Nerlakanti et al. MOLECULAR CANCER THERAPEUTICS
- DUB3 Promotes BET Inhibitor Resistance and Cancer Progression by Deubiquitinating BRD4
- (2018) Xin Jin et al. MOLECULAR CELL
- ZFX Mediates Non-canonical Oncogenic Functions of the Androgen Receptor Splice Variant 7 in Castrate-Resistant Prostate Cancer
- (2018) Ling Cai et al. MOLECULAR CELL
- Germline DNA Repair Mutations and Response to Hormonal Therapy in Advanced Prostate Cancer
- (2017) Emmanuel S. Antonarakis EUROPEAN UROLOGY
- Structural basis of PROTAC cooperative recognition for selective protein degradation
- (2017) Morgan S Gadd et al. Nature Chemical Biology
- Prostate cancer–associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4
- (2017) Xiangpeng Dai et al. NATURE MEDICINE
- Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT–mTORC1 activation
- (2017) Pingzhao Zhang et al. NATURE MEDICINE
- Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors
- (2017) Hana Janouskova et al. NATURE MEDICINE
- Androgen Receptor Deregulation Drives Bromodomain-Mediated Chromatin Alterations in Prostate Cancer
- (2017) Alfonso Urbanucci et al. Cell Reports
- Treatment strategies for DNA repair-deficient prostate cancer
- (2017) Benjamin A. Teply et al. Expert Review of Clinical Pharmacology
- The loss of Ezh2 drives the pathogenesis of myelofibrosis and sensitizes tumor-initiating cells to bromodomain inhibition
- (2016) Goro Sashida et al. JOURNAL OF EXPERIMENTAL MEDICINE
- BET Bromodomain Inhibitors Enhance Efficacy and Disrupt Resistance to AR Antagonists in the Treatment of Prostate Cancer
- (2016) I. A. Asangani et al. MOLECULAR CANCER RESEARCH
- Potent and selective bivalent inhibitors of BET bromodomains
- (2016) Michael J Waring et al. Nature Chemical Biology
- Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer
- (2016) Himisha Beltran et al. NATURE MEDICINE
- Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer
- (2016) Colin C. Pritchard et al. NEW ENGLAND JOURNAL OF MEDICINE
- BET protein inhibitor JQ1 inhibits growth and modulates WNT signaling in mesenchymal stem cells
- (2016) Saeed Alghamdi et al. Stem Cell Research & Therapy
- Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy
- (2015) Elias E. Stratikopoulos et al. CANCER CELL
- Combined MYC Activation and Pten Loss Are Sufficient to Create Genomic Instability and Lethal Metastatic Prostate Cancer
- (2015) Gretchen K. Hubbard et al. CANCER RESEARCH
- Integrative Clinical Genomics of Advanced Prostate Cancer
- (2015) Dan Robinson et al. CELL
- The Molecular Taxonomy of Primary Prostate Cancer
- (2015) Adam Abeshouse et al. CELL
- Non-canonical Bromodomain within DNA-PKcs Promotes DNA Damage Response and Radioresistance through Recognizing an IR-Induced Acetyl-Lysine on H2AX
- (2015) Li Wang et al. CHEMISTRY & BIOLOGY
- Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4
- (2015) Jing Lu et al. CHEMISTRY & BIOLOGY
- NF- B2/p52:c-Myc:hnRNPA1 Pathway Regulates Expression of Androgen Receptor Splice Variants and Enzalutamide Sensitivity in Prostate Cancer
- (2015) N. Nadiminty et al. MOLECULAR CANCER THERAPEUTICS
- Transcriptional plasticity promotes primary and acquired resistance to BET inhibition
- (2015) Philipp Rathert et al. NATURE
- BET inhibitor resistance emerges from leukaemia stem cells
- (2015) Chun Yew Fong et al. NATURE
- DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
- (2015) Joaquin Mateo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting chromatin binding regulation of constitutively active AR variants to overcome prostate cancer resistance to endocrine-based therapies
- (2015) Siu Chiu Chan et al. NUCLEIC ACIDS RESEARCH
- The oncogene ERG: a key factor in prostate cancer
- (2015) P Adamo et al. ONCOGENE
- Phthalimide conjugation as a strategy for in vivo target protein degradation
- (2015) G. E. Winter et al. SCIENCE
- Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer.
- (2015) Anastasia Wyce et al. Oncotarget
- The Mechanisms behind the Therapeutic Activity of BET Bromodomain Inhibition
- (2014) Junwei Shi et al. MOLECULAR CELL
- Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer
- (2014) Irfan A. Asangani et al. NATURE
- AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
- (2014) Emmanuel S. Antonarakis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Brd4 activates P-TEFb for RNA polymerase II CTD phosphorylation
- (2014) Friederike Itzen et al. NUCLEIC ACIDS RESEARCH
- DNA Double Strand Breaks as Predictor of Efficacy of the Alpha-Particle Emitter Ac-225 and the Electron Emitter Lu-177 for Somatostatin Receptor Targeted Radiotherapy
- (2014) Franziska Graf et al. PLoS One
- Bromodomains as therapeutic targets in cancer
- (2013) I. Barbieri et al. Briefings in Functional Genomics
- The bromodomain protein Brd4 insulates chromatin from DNA damage signalling
- (2013) Scott R. Floyd et al. NATURE
- Androgen Receptor Promotes Ligand-Independent Prostate Cancer Progression through c-Myc Upregulation
- (2013) Lina Gao et al. PLoS One
- Histone Recognition and Large-Scale Structural Analysis of the Human Bromodomain Family
- (2012) Panagis Filippakopoulos et al. CELL
- Bromodomain-dependent stage-specific male genome programming by Brdt
- (2012) Jonathan Gaucher et al. EMBO JOURNAL
- High tissue density of FOXP3+ T cells is associated with clinical outcome in prostate cancer
- (2012) Anna Flammiger et al. EUROPEAN JOURNAL OF CANCER
- The bromodomain interaction module
- (2012) Panagis Filippakopoulos et al. FEBS LETTERS
- BRD4 is an atypical kinase that phosphorylates Serine2 of the RNA Polymerase II carboxy-terminal domain
- (2012) B. N. Devaiah et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Androgen Receptor Gene Expression in Prostate Cancer Is Directly Suppressed by the Androgen Receptor Through Recruitment of Lysine-Specific Demethylase 1
- (2011) Changmeng Cai et al. CANCER CELL
- BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
- (2011) Jake E. Delmore et al. CELL
- The Brd4 Extraterminal Domain Confers Transcription Activation Independent of pTEFb by Recruiting Multiple Proteins, Including NSD3
- (2011) S. Rahman et al. MOLECULAR AND CELLULAR BIOLOGY
- PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis
- (2011) N. Ilic et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Targeting MYC dependence in cancer by inhibiting BET bromodomains
- (2011) J. A. Mertz et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor
- (2010) P. A. Watson et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Genetic alterations and changes in expression of histone demethylases in prostate cancer
- (2010) Hanna E. Suikki et al. PROSTATE
- ETS Gene Fusions in Prostate Cancer: From Discovery to Daily Clinical Practice
- (2009) Scott A. Tomlins et al. EUROPEAN UROLOGY
- Synthetic Lethality — A New Direction in Cancer-Drug Development
- (2009) J. Dirk Iglehart et al. NEW ENGLAND JOURNAL OF MEDICINE
- Splicing of a Novel Androgen Receptor Exon Generates a Constitutively Active Androgen Receptor that Mediates Prostate Cancer Therapy Resistance
- (2008) S. M. Dehm et al. CANCER RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started